Physician-initiated clinical trial in patients with 5-aminolevulinic acid-induced ATR-X syndrome.
Exploratory study to investigate the safety and efficacy of NPJ005 in patients with ATR-X syndrome. - IACT21003 Exploratory study to investigate the safety and efficacy of NPJ005 in patients with ATR-X syndrome. ...
The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia
The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia - The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia - The Safety ...
Sideroblastic anemia (congenital and acquired)
Food supplement containing 150 mg of ALA phosphate was given per day for 24 weeks. For the evaluation of efficacy and safety, medical examinations as well as urine and blood tests will be performed prior to administration of ALA, then at 2 and 4 weeks, and thereafter every month (up to 12 months). Food supplement containing 150 mg of ALAphosphate was given per day for 24 weeks. For the evaluation ...
Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine
A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic ane ...
A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia - Efficacy and safety of 5-ALA phosphate in patients with sideroblastic anemia A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic ane ...
sideroblastic anemia
Orally intake a 150 mg 5-aminolevulinic acid phosphate capsule once a day for up to 24 weeks.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University